Overview

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

Status:
Completed

Trial end date:
2021-05-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

AbCellera Biologics Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Shanghai Junshi Bioscience Co., Ltd.